LONDON, United Kingdom, June 3, 2026
Johnson & Johnson has announced positive late-breaking results from its Phase 2 JASMINE study, demonstrating that nipocalimab significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) and maintained clinical benefits through 52 weeks of treatment. The findings, presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, mark an important milestone for the investigational therapy, which is the first and only neonatal Fc receptor (FcRn) blocker studied in SLE. The results provide compelling evidence that targeting pathogenic immunoglobulin G (IgG) autoantibodies may offer a novel treatment approach for a disease that affects millions of people worldwide and can lead to irreversible organ damage. The study’s success further supports the advancement of the ongoing Phase 3 GARDENIA trial, which is currently recruiting patients globally.
Phase 2 JASMINE Trial Meets Primary Endpoint
The JASMINE trial successfully achieved its primary endpoint at Week 24, demonstrating a greater proportion of patients receiving nipocalimab 15 mg/kg plus background therapy achieved a response based on the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) compared with placebo. Importantly, the clinical benefits extended beyond the primary analysis period and remained durable through Week 52. Among patients who tested positive for lupus-associated autoantibodies—representing approximately 80% of individuals living with SLE—the treatment delivered even stronger outcomes.
At Week 52, 58.2% of autoantibody-positive patients receiving nipocalimab achieved an SRI-4 response, compared with 36.1% in the placebo group. Additionally, a significantly higher proportion of patients achieved Lupus Low Disease Activity State (LLDAS), a clinically meaningful measure increasingly recognized as a key treatment target in lupus management. These findings suggest that nipocalimab may offer sustained disease control while addressing underlying immune mechanisms driving disease progression.
Novel FcRn Blockade Targets Root Cause of Disease
Advertisement
Nipocalimab is designed to selectively block the neonatal Fc receptor (FcRn), reducing circulating pathogenic IgG autoantibodies and immune complexes responsible for chronic inflammation and tissue damage in lupus. Unlike traditional immunosuppressive therapies that broadly suppress immune function, nipocalimab aims to reduce harmful autoantibodies while preserving critical immune defenses. Researchers believe this immunoselective mechanism may provide a more targeted approach to treating autoimmune diseases.
The JASMINE study represents the first proof-of-concept demonstration that FcRn blockade can effectively reduce disease activity in systemic lupus erythematosus, providing clinical, pharmacodynamic, and biomarker evidence supporting further development. Investigators also reported reductions in pathogenic autoantibody levels consistent with the drug’s proposed mechanism of action, reinforcing its potential to address the underlying biology of lupus rather than merely controlling symptoms.
Safety Profile Supports Continued Phase 3 Development
In addition to efficacy outcomes, nipocalimab demonstrated a safety profile consistent with previous clinical studies, with no new safety signals identified during the trial. The most frequently reported adverse events included nasopharyngitis, headache, urinary tract infection, and nausea. Johnson & Johnson noted that the favorable balance of efficacy and safety contributed to the U.S. FDA granting Fast Track Designation for SLE earlier in 2026, recognizing the significant unmet medical need in this patient population. SLE remains one of the most complex autoimmune diseases, affecting approximately 3 to 5 million people globally, with women accounting for the vast majority of cases. Despite advances in treatment, many patients continue to experience persistent disease activity, debilitating fatigue, and progressive organ damage.
The encouraging Phase 2 findings position nipocalimab as a potentially important new therapeutic option and strengthen confidence in the ongoing Phase 3 GARDENIA study. If successful, the therapy could represent a major advancement in lupus treatment by offering durable disease control through targeted reduction of pathogenic autoantibodies.
Source: Johnson & Johnson press release
